ESPERITE (ESP) : L1 Capital subscribes to the 13th tranche of investment today
Amsterdam, The Netherlands – 16 January 2018
As Esperite N.V. (Euronext: ESP, “Esperite” or “the Group”) is completing its strategy to concentrate its laboratory activities in its state of the art and fully certified facilities in Geneva, its Belgium subsidiary company CryoSave Labs (“CSL” or the”Company”) is left with no commercial activity and its facility in Neil has become redundant.
Amsterdam, The Netherlands – 10 January 2018
ESPERITE (ESP) : L1 Capital subscribes to the 12th tranche of investment today
Amsterdam, The Netherlands – 10 January 2018
ESPERITE (ESP): CEO Frederic Amar converts a portion of his Loan Note into 1.5 million shares.
Amsterdam, the Netherlands – 8 January 2018
ESPERITE N.V. (Euronext: ESP, ‘ESPERITE’, or ‘the Group’) declares the issuance of a convertible loan note of EUR 400’000 to CEO Frederic Amar who has completed the additional financing announced on October 2017.
Amsterdam, the Netherlands – 5 January 2018
Further support of Esperite’s strategy, commercial activities and development of innovative technologies in the field of genetics and regenerative medicines
Amsterdam, The Netherlands – 22 December 2017
Esperite N.V. (ESP) nominates Accon AVM as Auditor.
Amsterdam, the Netherlands – 27 November 2017
Esperite has taken all the necessary measures after the difficult end of the first semester. The company invests in its technology and prepares to grow again.
Amsterdam, The Netherlands – 17 November 2017
ESPERITE (ESP) : L1 Capital invests for total EUR 500K today by subscribing to the Tenth tranche (EUR 250K) and shows confidence by investing additionally EUR 250K under the same conditions.
Amsterdam, The Netherlands – 9 November 2017
ESPERITE (ESP) : L1 Capital subscribes to the Ninth tranche of investment today
Amsterdam, The Netherlands – 30 October 2017
